Genomics

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

At HLTH Europe, Saudi Arabia's KFSH revealed more than just a radiology AI. It unveiled a full ecosystem, proving how integrated tech transforms patient care.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

In memory of her daughter Elora, a mother's foundation joins a global research network, turning personal tragedy into a collaborative fight against a rare cancer.

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

An Arizona nonprofit’s innovative sweepstakes, driven by a personal mission, is accelerating gene therapy for childhood blindness. A new model for impact.

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

For millions, the 'why' behind infertility remains a mystery. New genomic mapping tech is finally providing answers, changing the landscape of family planning.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

A Swedish firm's novel cell therapy is the first of its kind in Europe, challenging the grim prognosis of pancreatic cancer and testing a new model for biotech.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

One year in, the Facial Pain Registry has gathered data from 740 patients, creating an unprecedented resource to fight one of medicine's most misunderstood conditions.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

As AI fatigue hits markets, one sector sees a real breakthrough. Taiwan's TFC is using AI to boost IVF success, offering new hope to infertile couples.

One in six people globally faces infertility, yet a pervasive stigma silences their struggle. A worldwide movement is now uniting millions to demand change.